INTELLIA THERAPEUTICS

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022

06 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

05 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

05 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

20 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

13 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

22 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

05 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

04 Nov 2021 06:30:01 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

28 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

21 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress

20 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

13 Oct 2021 06:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

06 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference

27 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia

16 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present at September Healthcare Investor Conferences

31 Aug 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

05 Aug 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

29 Jul 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

02 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

29 Jun 2021 20:08:30 By Nasdaq GlobeNewswire